155369-11-2

Basic information

• Product Name: Fmoc-3-Aminomethylbenzoic acid
• Synonyms: RARECHEM EM WB 0055;FMOC-3-AMB-OH;FMOC-(3-AMINOMETHYL)-BENZOIC ACID;FMOC-MAMB;FMOC-MAMB-OH;3-(FMOC-AMINOMETHYL)BENZOIC ACID;3-(9-FLUORENYLMETHYLOXYCARBONYL-AMINOMETHYL)BENZOIC ACID;3-(N-FMOC-AMINOMETHYL)BENZOIC ACID
• CAS NO: 155369-11-2
• Molecular Formula: C₂₃H₁₉NO₄
• Molecular Weight: 373.4
• Product Categories: Amino Acids;Aromatic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 155369-11-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 631.6 °C at 760 mmHg
• Flash Point: 335.8 °C
• Appearance: /
• Density: 1.296 g/cm³
• Vapor Pressure: 1.43mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• PKA: 4.20±0.10(Predicted)
• BRN: 6825025
• CAS DataBase Reference: Fmoc-3-Aminomethylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-3-Aminomethylbenzoic acid(155369-11-2)
• EPA Substance Registry System: Fmoc-3-Aminomethylbenzoic acid(155369-11-2)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 155369-11-2(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Fmoc-3-aminomethylbenzoic acid

InChI:InChI=1/C5H5FN2/c6-4-2-1-3-8-5(4)7/h1-3H,(H2,7,8)

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 2393-20-6 3-aminomethylbenzoic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 919529-61-6 N-amino(3-{[(fluoren-9-ylmethoxy)carbonylamino]-methyl}phenyl)carboxamide trifluoroacetic acid salt 
• 1252806-70-4 GB₁₁₀ 
• 1246611-80-2 C₄₂H₆₁N₉O₉ 
• 1246611-79-9 C₄₅H₆₃N₉O₁₂ 
• 937207-76-6 C₃₇H₄₄N₄O₆S 
• 1133164-66-5 FITC-[3-aminomethylbenzoyl]-pTyr-Gln-Gly-Leu-Ser-amide 

Relevant articles and documents

Discovery of Novel Nonpeptidic PAR2 Ligands

Proteinase-activated receptor 2 (PAR2) is a class A G protein-coupled receptor whose activation has been associated with inflammatory diseases and cancer, thus representing a valuable therapeutic target. Pathophysiological roles of PAR2 are often characterized using peptidic PAR2 agonists. Peptidic ligands are frequently unstable in vivo and show poor bioavailability, and only a few approaches toward drug-like nonpeptidic PAR2 ligands have been described. The herein-described ligand 5a (IK187) is a nonpeptidic PAR2 agonist with submicromolar potency in a functional assay reflecting G protein activation. The ligand also showed substantial β-arrestin recruitment. The development of the compound was guided by the crystal structure of PAR2, when the C-terminal end of peptidic agonists was replaced by a small molecule based on a disubstituted phenylene scaffold. IK187 shows preferable metabolic stability and may serve as a lead compound for the development of nonpeptidic drugs addressing PAR2.